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Summary
Background Antithrombotic (anticoagulant or antiplatelet) therapy is withheld from some patients with cerebral caver­
nous malformations, because of uncertainty around the safety of these drugs in such patients. We aimed to establish 
whether antithrombotic therapy is associated with an increased risk of intracranial haemorrhage in adults with cerebral 
cavernous malformations.
Methods In this population­based, cohort study, we used data from the Scottish Audit of Intracranial Vascular 
Malformations, which prospectively identified individuals aged 16 years and older living in Scotland who were first 
diagnosed with a cerebral cavernous malformation during 1999–2003 or 2006–10. We compared the association 
between use of antithrombotic therapy after first presentation and the occurrence of intracranial haemorrhage or 
persistent or progressive focal neurological deficit due to the cerebral cavernous malformations during up to 15 years 
of prospective follow­up with multivariable Cox proportional hazards regression assessed in all individuals identified 
in the database. We also did a systematic review and meta­analysis, in which we searched Ovid MEDLINE and Embase 
from database inception to Feb 1, 2019, to identify comparative studies to calculate the intracranial haemorrhage 
incidence rate ratio according to antithrombotic therapy use. We then generated a pooled estimate using the inverse 
variance method and a random effects model.
Findings We assessed 300 of 306 individuals with a cerebral cavernous malformation who were eligible for study. 
61 used antithrombotic therapy (ten [16%] of 61 used anticoagulation) for a mean duration of 7·4 years (SD 5·4) during 
follow­up. Antithrombotic therapy use was associated with a lower risk of subsequent intracranial haemorrhage or 
focal neurological deficit (one [2%] of 61 vs 29 [12%] of 239, adjusted hazard ratio [HR] 0·12, 95% CI 0·02–0·88; 
p=0·037). In a meta­analysis of six cohort studies including 1342 patients, antithrombotic therapy use was associated 
with a lower risk of intracranial haemorrhage (eight [3%] of 253 vs 152 [14%] of 1089; incidence rate ratio 0·25, 
95% CI 0·13–0·51; p<0·0001; I²=0%).
Interpretation Antithrombotic therapy use is associated with a lower risk of intracranial haemorrhage or focal 
neurological deficit from cerebral cavernous malformations than avoidance of antithrombotic therapy. These findings 
provide reassurance about safety for clinical practice and require further investigation in a randomised controlled trial.
Funding UK Medical Research Council, Chief Scientist Office of the Scottish Government, The Stroke Association, 
Cavernoma Alliance UK, and the Remmert Adriaan Laan Foundation.
Copyright © 2019 The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Cerebral cavernous malformations (CCMs) are the 
second com monest incidental vascular finding on brain 
MRI.1 CCMs can cause stroke due to either intracranial 
haemor rhage or non-haemorrhagic focal neurological 
deficit attributable to the anatomical loca tion of the CCM.2 
The risk of these strokes is higher for people with CCMs 
that have already caused an intracranial haemorrhage and 
for those with a brainstem CCM.3
Around a quarter of patients with CCMs could have an 
indic ation for antithrombotic (anticoagulant or anti platelet) 
therapy for the prevention of occlu sive vascular disease.4–7 
Anticoagulant therapy can be used for prevention of 
systemic embolism in patients with atrial fibrillation or 
venous thromboembol ism, and antiplatelet therapy for 
second ary prevention after ischaemic cerebro vascular and 
cardiovascular dis eases. However, few data are available 
on the effect of antithrombotic therapy on the risk of 
intracranial haemor rhage in adults with a CCM, leaving it 
diffi cult to create guidelines with strong recommendations,8 
despite expert opinion that anticoagulation is contraindi-
cated in patients with CCMs on the basis of a case report.9
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Some observational studies have found non-significant 
associations between the use of long-term antithrombotic 
therapy and a lower risk of intracranial haemorrhage 
from a CCM,4–7 but these studies were mostly small, 
retrospective, hospital-based studies that investigated 
associations with intracranial haemorrhage alone (omitt-
ing non-haemorrhagic focal neurological deficits). Both 
haemorrhagic and non-haemorrhagic focal neuro logical 
deficits might be triggered by thrombosis in the CCM or 
an associated venous malformation,2 raising the hypoth-
esis that antithrombotic drugs might benefit patients 
with CCMs.
We set out to investigate the association between 
antithrombotic therapy and intracranial haemorrhage or 
focal neurological deficit in adults with CCMs in a large 
prospective, population-based cohort study with long-
term follow-up. We also sought to maximise the precision 
of the estimated association between antithrombotic 
therapy and intracranial haemorrhage from CCMs by 
doing a systematic review and combining the population-
based data with the hospital-based data in a meta-analysis.
Methods
Study design and participants in the population-based 
cohort study
In the population-based cohort study, we used anony-
mous data from the Scottish Audit of Intracranial 
Vascular Malformations (SAIVMs), which is an ongoing 
National Health Service clinical audit of the care and 
outcome of people aged 16 years or older who were 
first diagnosed with any type of intracranial vascular 
malformation during 1999–2003 or 2006–10 while liv ing 
in Scotland, UK (case ascertainment did not occur 
2004–05, but follow-up continued uninterrupted).10,11 In 
the current analysis, we included every individual aged 
16 years or older with a first-in-a-lifetime definite diag-
nosis of CCM identified by the SAIVMs. Details of how 
the SAIVMs collected the data, recruited, and followed-
up individuals in the data base have been published 
previously.11 The Multicentre Research Ethics Committee 
for Scotland (MREC/98/0/48) and the Fife and Forth 
Valley Research Ethics Committee (08/S0501/76) app-
roved the observational studies (to which an opt-out 
consent policy applied) and postal question naire studies 
(which required opt-in consent). The study protocol is 
available online.
Procedures of the population-based cohort study
We categorised the type of first clinical presentation by 
the symptoms and signs that led to the initial CCM 
diagnosis (regardless of earlier events that might, in 
retrospect, have been attributable to a CCM).11 One of 
three neuro radiologists verified CCM diagnoses with 
reference to accepted criteria,12,13 but if they were not 
certain about the CCM diag nosis, the MRI was reviewed 
by another neuroradiologist independently, and a con-
sensus opinion reached on diagnostic certainty. The 
neuroradiologist collected data for CCM location and 
imaging evidence of acute, subacute, or chronic intra-
cranial haemorrhage. The inception point was the time of 
first clinical pre sentation.11 We collected demographic 
information and medical history from medical records at 
baseline, and identified treatment and outcomes using 
annual pros pective surveillance of hospital records, 
primary care practitioner records, and postal question-
naires to both the patients and their primary care 
Research in context
Evidence before this study
Expert opinion recommends against the use of anticoagulant 
therapy for patients with cerebral cavernous malformations 
(CCMs) on the basis of a single case report. 2017 guidelines 
found few data for the risk of antithrombotic (anticoagulant or 
antiplatelet) therapy use in people with a CCM (class III, level C). 
We searched Ovid MEDLINE and Embase for systematic reviews, 
meta-analyses, and articles published before Feb 1, 2019, with 
no language restrictions, reporting original data for intracranial 
haemorrhage and person-years of follow-up according to 
antithrombotic therapy use in patients with a CCM. We used a 
comprehensive search strategy, limited to humans, combining 
terms for CCMs and antithrombotic therapy (appendix p 2–3). 
We also searched international registries and reference lists of 
relevant publications. We did not find any systematic reviews or 
meta-analyses, but we found four non-randomised, 
hospital-based, predominantly retrospective comparative 
cohort studies. Each study found a non-significant association 
between antithrombotic therapy use and lower risk of 
subsequent intracranial haemorrhage.
Added value of this study
To our knowledge, this is the first prospective, 
population-based study investigating this question, in which 
we found an association between antithrombotic therapy use 
and a lower risk of intracranial haemorrhage or focal 
neurological deficit due to a CCM (adjusted hazard ratio 0·12, 
95% CI 0·02–0·88; p=0·037). Furthermore, our systematic 
review and meta-analysis of data for 1342 patients confirmed 
an association between antithrombotic therapy use and a lower 
risk of intracranial haemorrhage (incidence rate ratio 0·25, 
95% CI 0·13–0·51; p<0·0001).
Implications of all the available evidence
We did not find evidence of a harmful association between the 
use of antithrombotic therapy and intracranial haemorrhage in 
adults with CCM, which is reassuring when antithrombotic 
therapy is required by patients with CCMs for other indications. 
The possibility that antithrombotic therapy might be beneficial 
for the prevention of intracranial haemorrhage from a CCM 
requires investigation in a randomised controlled trial.
See Online for appendix
For the study protocol see 
http://www.saivms.scot.nhs.uk/
spDesign.asp
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practitioners. We retrospectively collected data for anti-
thrombotic therapy use from these data sources. Long-
term antithrombotic therapy use was defined as the 
prescription and receipt of anticoagulant or antiplatelet 
therapy for at least 90 days at any time after inception, 
but before the first out come event or the end of follow-up 
(if an outcome event did not occur). The primary out-
come was a composite of new stroke due to intracranial 
haemorrhage (confirmed by acute or subacute haem-
orrhage on brain imaging consistent with the time of 
symptom onset) or new persistent or pro gressive focal 
neurological deficit definitely attributable to the location 
of the CCM (but without evidence of a new haemorrhage 
on brain imaging).2,11 We included focal neurological 
deficits due to a CCM because these events are often 
of simi lar severity to intracranial haemorrhage due to 
a CCM; further more, focal neurological deficits might 
be undetected haemorrhages or possibly throm bosis 
that might be affected by antithrombotic therapy.11 
We quanti fied intracranial haemorrhage alone for our 
second ary outcome to facilitate comparison with other 
studies. Two investigators assessed outcome events using 
available clinical, radiological, and pathological infor-
mation, masked to antithrombotic therapy use. The 
cause of death was established using death certificates, 
autopsy records (if post-mortem examination had been 
done), clinical records, and any brain imaging that had 
been done.
Search strategy and selection criteria for the systematic 
review
We searched Ovid MEDLINE and Embase from data-
base inception until Feb 1, 2019, to identify comparative 
studies des cribing the association between antithrom -
botic therapy use in patients with CCM and intra cran ial 
haemorrhage (appendix p 2–3). We also searched 
the Cochrane Library, ClinicalTrials.gov, International 
Standard Randomised Controlled Trials Number Registry, 
and did a manual search of the bibliographies of relevant 
publications. We considered publications for inclusion if 
they reported original data for intracranial haemorrhage 
and person-years of follow-up accord ing to antithrombotic 
therapy use. We excluded case reports. There was no 
language restriction. Two authors (SMZ and CRH) did the 
literature search and quality assessment independently 
and completed a data extraction form. Any disagreements 
in the data were resolved by a third reviewer (RA-SS). 
We extracted data for the following characteristics: 
publication char acteristics, countries or regions of the 
study, study design, inclusion criteria, patient character-
istics, sample size, antithrombotic therapy use and type, 
duration and completeness of follow-up, and clinical 
outcomes. We assessed the quality of the observational 
studies using the Cochrane risk of bias tool. The primary 
outcome was the occurrence of intracranial haemorrhage, 
as defined by the study, after CCM diagnosis during all 
available follow-up. 
Statistical analysis 
We compared baseline characteristics and outcomes 
between patients using or not using antithrombotic 
therapy in the population-based cohort study to detect 
potential differences between the two groups. Continuous 
variables with a normal distribution are reported as the 
mean and SD or the median and IQR. Categorical 
variables are reported as percentages with their corres-
ponding 95% CIs. For statistical comparisons between 
the two groups, we used the χ² test or, in case of low 
frequencies, Fisher’s exact test. For continuous variables, 
we used an unpaired t test or Mann-Whitney U test, as 
indicated. We quantified completeness of the follow-up 
data we had accrued as a proportion of the potential 
follow-up that could have been obtained before the end of 
the timeframe for these analyses.14 We used life tables and 
Kaplan-Meier survival analysis up to 15 years of follow-up, 
followed by multivariable Cox regression analysis if 
proportional hazard assump tions were satisfied,15 with 
prespecified adjustment for type of CCM presentation and 
location of CCM (dichotomised as brainstem [midbrain, 
pons, or medulla] or other locations).3 We also adjusted for 
age because of the baseline difference between patients 
according to antithrombotic therapy use. We censored 
follow-up at CCM treatment with neurosurgical excision 
or stereo tactic radiosurgery, or at death not due to an 
outcome event. 
For each study in the systematic review, we calculated 
the incidence rate ratio (IRR) of intracranial haemorrhage 
during the total number of person-years of follow-up for 
antithrombotic therapy users versus non-users. We 
generated a pooled estimate by meta-analysis using the 
inverse variance method and a random effects model. We 
considered two-sided probability values of less than 
0·05 significant. We quantified inconsistency between 
studies using the I² statistic. We analysed all data using 
Review Manager 5.3 or IBM SPSS Statistics version 25.0. 
Role of the funding source
The funders of this study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results
306 adult residents in Scotland were newly diagnosed 
with a CCM during 1999–2003 or 2006–10. The median 
age of the 306 patients at the initial presentation that led 
to CCM diagnosis was 44·0 years (IQR 32·0–58·0) and 
160 (52%) were women. After excluding six adults whose 
CCM was diagnosed incidentally at autopsy and who did 
not contribute follow-up data, we included 300 adults 
in our analyses (table 1). Of these 300 adults, 61 used 
antithrombotic therapy (ten [16%] of 61 used anti-
coagulation, alone or in combination with antiplatelet 
therapy). 32 (53%) of these 61 adults were already using 
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antithrombotic therapy at the time of CCM diagnosis. 
Patients who used antithrombotic therapy were older, the 
type of presentation of their CCM was more likely 
to be incidental and less likely to be with intracranial 
haemorrhage, and they were more likely to have a his-
tory of hypertension, ischaemic heart disease, ischaemic 
cerebrovascular disease, and atrial fibrillation than 
patients never using antithrombotic therapy, but there 
were no significant differences in sex, CCM multiplicity, 
and CCM brainstem location at baseline (table 1). 
We followed up the 300 adults with a CCM who were 
alive at initial presentation for the primary outcome of 
intracranial haemorrhage or focal neurological deficit 
definitely related to CCM until Mar 7, 2019, for a mean 
duration of 11·6 years (SD 5·0) until first outcome or 
censoring (total 3634 person-years of 3843 potential 
person-years, for an overall median completeness of 
95%, IQR 94–99).14 All intracranial haemorrhages were 
intracerebral. The mean duration of antithrombotic 
therapy use during follow-up was 7·4 years (SD 5·4). 
One patient using antiplatelet therapy since CCM 
diagnosis developed the primary outcome while still 
taking antiplatelet therapy (one [2%] of 61 anti-
thrombotic therapy users during 706 person-years of 
follow-up), which was less frequent than in patients not 
using anti thrombotic therapy (29 [12%] of 239 dur-
ing 2208 person-years of follow-up; log-rank p=0·011; 
figure 1). After confirming the proportional hazards 
assumption (appendix p 4) and adjusting for age, type of 
presentation, and CCM location, use of antithrombotic 
therapy was associated with a lower risk of the primary 
outcome (adjusted HR 0·12, 95% CI 0·02–0·88; p=0·037; 
table 2). Post-hoc sensitivity analyses revealed similar, 
but non-significant associations between antithrombotic 
therapy and the primary outcome when antithrombotic 
ther apy was a time-dependent covariate (adjusted HR 
0·30, 95% CI 0·04–2·32; p=0·25), when the cohort was 
res tricted to brainstem CCMs (adjusted HR 0·16, 
0·02–1·28; p=0·084; appendix p 5), when the cohort 
was restricted to patients presenting with intracranial 
haemorrhage (adjusted HR 0·41, 0·05–3·21; p=0·40; 
appendix p 6), when the cohort was restricted to the 
29 patients who started anti thrombotic therapy after first 
presentation (unadjusted HR 0·04, 95% CI 0·00–4·87; 
p=0·189; appendix p 7), when the cohort was restricted to 
the 228 patients without a brainstem CCM or intracranial 
haemorrhage at presen tation (unadjusted HR 0·033, 
0·00–34·94, p=0·34), and when analysing the poten-
tial competing risks of death and CCM treatment 
as outcomes (adjusted HR 0·59, 0·33–1·03; p=0·061; 
appendix p 8). We were unable to do sensitivity analyses 
of the primary outcome according to the type of 
anti thrombotic therapy because no patients using anti-
coagulant therapy had the primary outcome. In analyses 
of the secondary outcome of intracranial haem orrhage 
alone (in which one patient, who had not used 
anti thrombotic therapy before devel oping a focal neuro-
logical deficit [primary outcome], used anti thrombotic 
therapy after wards and was analysed accordingly for the 
secondary outcome), there was no significant association 
between antithrombotic therapy use and a lower risk of 
intracranial haemorrhage (one [2%] of 62 patients during 
726 person-years of follow-up vs 18 [8%] of 238 dur-
ing 2342 person-years of follow-up; log-rank p=0·070; 
appendix p 8–9).
Used antithrombotic 
therapy after presentation 
(n=61)
Never used 
antithrombotic therapy 
after presentation (n=239)
p value
Sex 0·13
Women 27 (44%) 132 (55%) ··
Men 34 (56%) 107 (45%) ··
Age, years 57·0 (45·5–65·0) 39·0 (31·0–53·0) <0·0001
Comorbidities
Hypertension 32 (52%) 28 (12%) <0·0001
Ischaemic heart disease 24 (39%) 6 (3%) <0·0001
Ischaemic stroke or transient 
ischaemic attack
21 (34%) 4 (2%) <0·0001
Atrial fibrillation 7 (11%) 1 (<1%) <0·0001
Mechanical heart valve 0 0 ··
Type of CCM presentation
Incidental 39 (64%) 90 (38%) <0·0001
Focal neurological deficit 4 (7%) 27 (11%) 0·28
Epileptic seizure 13 (21%) 75 (31%) 0·12
Intracranial haemorrhage 5 (8%) 47 (20%) 0·035
CCM imaging characteristics
Multiple CCM 16 (26%) 81 (34%) 0·25
Brainstem CCM 8 (13%) 26 (11%) 0·62
Data are n (%) or median (IQR). CCMs=cerebral cavernous malformations. 
Table 1: Baseline characteristics of adults in the prospective population-based cohort study, stratified by 
use of antithrombotic therapy
Figure 1: Kaplan-Meier plot 
Risk of first intracranial haemorrhage or persistent or progressive focal neurological deficit due to cerebral 
cavernous malformations according to antithrombotic therapy use during 15 years of follow-up in the Scottish 
Audit of Intracranial Vascular Malformations. 
   Number at risk 
(number of events
 in the next 2 years)
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p=0·037
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Of the 180 records identified in the systematic review, we 
selected eight potentially relevant studies, of which four 
met our inclusion criteria in our meta-analysis (table 2). 
Studies were exclusively single-centre, hospital-based, 
non-randomised cohort studies at moderate to high risk of 
bias (appendix p 10).4–7 We included these four studies, 
unpublished data from the Mayo Clinic (Rochester, MN, 
USA),16 and the SAIVMs cohort study in a meta-analysis 
of 1342 patients: 1089 [81%] did not use antithrom-
botic therapy (152 intracranial haemorrhages occurred 
during 6214 person-years), 46 [3%] used anticoagulant 
therapy (one intracranial haemorrhage occurred dur-
ing 260 person-years), and 207 [15%] used antiplatelet 
therapy alone (seven intracranial haemorrhages during 
1221 person-years; table 3). Baseline imbalances in this 
larger overall dataset were similar to SAIVMs: patients 
who used antithrombotic therapy were older, less often 
women (104 [41%] of 253 vs 603 [55%] of 1089; p<0·0001), 
and presented less often with intracranial haemorrhage 
(36 [14%] of 253 vs 316 [29%] 1089; p<0·0001) than patients 
who did not use antithrombotic therapy. Antithrombotic 
therapy use was associated with a lower risk of intracranial 
haemorrhage (all of which were intracerebral) from a CCM 
(eight [3%] of 253 vs 152 [14%] of 1089, IRR 0·25, 95% CI 
0·13–0·51; p<0·0001) with no inconsistency between 
studies (I²=0%; figure 2). Of the eight patients using anti-
thrombotic therapy, who had an intracranial haemorrhage 
during follow-up, one (13%) used anticoagulation and 
seven (88%) used antiplatelet therapy. In post-hoc sensi-
tivity analyses, we compared patients taking antiplatelet 
therapy alone with patients not taking antithrombotic 
therapy (IRR 0·30, 95% CI 0·15–0·62; p=0·0010) and 
Outcome events in 
sample
Log-rank 
p value
Unadjusted hazard ratio Adjusted hazard ratio* 
CCM location <0·0001 8·79 (4·29–17·99); p<0·0001 7·14 (3·14–16·27); p<0·0001
Brainstem 15/34 (44%) ·· ·· ··
Non-brainstem 15/266 (6%) ·· ·· ··
Type of CCM presentation <0·0001 6·36 (3·10–13·04); p<0·0001 3·20 (1·47–6·97); p=0·0033
Intracranial haemorrhage 15/52 (29%) ·· ·· ··
Other 15/248 (6%) ·· ·· ··
Age at presentation (per year increase) NA NA 1·00 (0·98–1·02); p=0·94 0·99 (0·97–1·02); p=0·53
Antithrombotic therapy use after presentation 0·011 0·12 (0·02–0·85); p=0·034 0·12 (0·02–0·88); p=0·037
Yes 1/61 (2%) ·· ·· ··
No 29/239 (12%) ·· ·· ··
Data are n/N (%) or hazard ratio (95% CI); p value. CCM=cerebral cavernous malformations. NA=not applicable.  *Adjusted for age, type of CCM presentation, and CCM 
location.
Table 2: Cox proportional hazards regression of associations with intracranial haemorrhage or persistent or progressive focal neurological deficit due to 
CCM during 15 years of follow-up in the Scottish Audit of Intracranial Vascular Malformations
Schneble et al, 20126 
(n=87) 
Flemming et al, 20135 
(n=292)
Wityk et al, 20147 
(n=96)
Bervini et al, 20184 
(n=365) 
Flemming et al, 201816 
(n=202)
SAIVMs cohort
(n=300)
Never used 
ATT
Ever used 
ATT
Never used 
ATT
Ever used 
ATT
Never used 
ATT
Ever used 
ATT
Never used 
ATT
Ever used 
ATT
Never used 
ATT
Ever used 
ATT
Never used 
ATT
Ever used 
ATT
N 71 (82%) 16 (18%) 252 (86%) 40 (14%) 74 (77%) 22 (23%) 294 (81%) 71 (19%) 160 (79%) 42 (21%) 238 (79%) 62 (21%)
Sex
Women 44 (62%) 6 (38%) 135 (54%) 19 (48%) 49 (66%) 9 (41%) 150 (51%) 19 (27%) 94 (59%) 23 (55%) 131 (55%) 28 (45%)
Men 27 (38%) 10 (62%) 117 (46%) 21 (52%) 25 (34%) 13 (59%) 144 (49%) 52 (73%) 66 (41%) 19 (45%) 107 (45%) 34 (55%)
Mean age, years (SD) 54·0 
(16·5)
68·4 
(16·1)
43·2 
(18·6)
62·4 
(13·2)
38·2 
(15·9)
53·0 
(15·5)
46·8 
(18·2)
62·4 
(15·8)
41·9 
(15·7)
51·4 
(16·2)
42·2 
(15·1)
54·5 
(14·9)
Presentation with 
haemorrhage
11 (15%) 0 69 (27%) 5 (13%) 23 (31%) 5 (23%) 102 (35%) 14 (20%) 64 (40%) 6 (14%) 47 (20%) 5 (8%)
Multiple CCM 27 (38%) 5 (31%) 51 (20%) 4 (10%) 17 (23%) 8 (36%) 48 (16%) 7 (10%) 45 (28%) 11 (26%) 81 (34%) 16 (26%)
Brainstem CCM location 20 (28%) 3 (19%) 21 (8%) 7 (18%) 21 (28%) 9 (41%) 57 (19%) 8 (11%) 52 (33%) 9 (21%) 25 (11%) 9 (15%)
Haemorrhage during 
follow-up 
9 (13%) 0 31 (12%) 1 (3%) 14 (19%) 1 (5%) 33 (11%) 1 (1%) 47 (29%) 4 (10%) 18 (8%) 1 (2%)
Person-years of 
follow-up 
205 82 1776 247 468 122 813 134 609 170 2342 726
Data are n (%) unless specified. CCM=cerebral cavernous malformations. ATT=antithrombotic therapy. SAIVMs=Scottish Audit of Intracranial Vascular Malformations. 
Table 3: Characteristics of cohort studies included in the meta-analysis
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patients taking anticoagulant therapy with patients 
not taking antithrombotic therapy (IRR 0·53, 0·19–1·52; 
p=0·24; appendix p 11). Antithrombotic therapy remained 
associated with a lower risk of intracranial haemorrhage in 
a post-hoc sensitivity analysis excluding the unpublished 
Mayo Clinic cohort (IRR 0·16, 0·06–0·42; p=0·00020).
Discussion
Antithrombotic therapy use was associated with a lower 
risk of intracranial haemorrhage or focal neurological 
deficit during long-term follow-up in a prospective 
population-based study of patients with CCMs, and 
antithrombotic therapy was associated with a lower risk 
of intracranial haemorrhage alone in a meta-analysis of 
six comparative cohort studies of patients with CCMs, 
with no inconsistency between their findings. 
These findings are consistent with previous, non-
significant associations observed in individual cohort 
studies of antiplatelet therapy for patients with CCM.5–7 
The addition of patients using anticoagulant therapy, 
and the paucity of intracranial haemorrhage outcomes 
among them, provides further reassurance about the use 
of any type of antithrombotic therapy for patients with an 
indication for these drugs, who also have a CCM.
The association between antithrombotic therapy and a 
lower risk of intracranial haemorrhage or focal neuro-
logical deficit from a CCM is consistent with the hypoth-
esis that these events might be triggered by thrombus 
formation in the dilated caverns of CCMs in which blood 
flow is slow, or thrombus in an associated venous mal-
formation.17,18 A similar patho physio logical mechanism 
underlies haemorrhagic infarcts in patients with cerebral 
venous thrombosis,19,20 which is treated with anticoagulation 
to improve outcome and reduce the risk of recurrence, 
regardless of the presence of haemorrhagic infarction.21 
Furthermore, antithrombotic therapy had similar, un-
expected effects after intracerebral haemorrhage in the 
RESTART trial (ISRCTN71907627),22 which excluded all 
but a very modest increase in the risk of recurrent 
intracerebral haemorrhage with ant iplatelet therapy for 
patients taking antithrombotic therapy for the preven-
tion of occlusive vascular disease when they developed 
intracerebral haemorrhage.
Our study has strengths, including a prospective, 
population-based cohort design with long-term follow-
up and outcome assessment masked to antithrombotic 
therapy use. Furthermore, we evaluated associations using 
all known available data, in a comprehensive systematic 
review and meta-analysis. Moreover, the meta-analysis had 
a large sample size, many outcomes, and a large number 
of person-years of follow-up to evaluate the association 
with pre cision, which was highly consistent between 
studies.
The non-randomised designs of all available studies 
resulted in systematic differences between patients who 
did, or did not, use antithrombotic therapy during follow-
up. These differences were likely to be, at least in part, 
due to selection bias (eg, patients without a history 
of intracranial haemorrhage were more likely to use 
antithrombotic therapy) and confounding by indication 
(eg, patients who used antithrombotic therapy were 
older, with a higher likelihood of the competing risk of 
death). However, we had prespecified statistical adjust-
ment of the findings in our population-based study for 
two of these potential confounders, and also adjusted for 
the imbalance in age, after which the associations we 
found remained significant. Although the findings of the 
cohort study were not significant in a variety of post-
hoc sensitivity analyses, the directi ons of the associ-
ations remained the same (with no suggestion of harm 
associated with antithrombotic therapy).
In the meta-analysis, we were unable to adjust for 
baseline imbalances, or explore risk in relation to either 
familial versus sporadic CCM or the time between 
presentation with intracranial haemorrhage and starting 
antithrombotic therapy, because we used aggregate, rather 
than individual patient data. Some of the studies were 
retrospective, which might have resulted in recall and 
information biases. Many of the patients might have used 
statins as secondary prevention for a cardiovascular or 
cerebrovascular disease, which have been suggested to 
reduce the risk of intracranial haemorrhage from CCM 
in animal models,23 although this effect has not been 
seen in humans.24 The small number of patients taking 
anticoagulant therapy in these studies (probably because 
of clinicians’ fears about these drugs in patients with a 
CCM) gave imprecise estimates of the association between 
anticoagulant therapy and intracranial haemorrhage 
during follow-up.
Our findings have implications for clinical practice. 
Although a review recommended that anticoagulation 
was contraindicated for people with CCM,3 our findings 
do not support this recommendation. The associations 
we have found are reassuring for the use of both types 
of antithrombotic therapy in clinical practice, in which 
Figure 2: Meta-analysis of the association between antithrombotic therapy use and the risk of intracranial 
haemorrhage from cerebral cavernous malformations in cohort studies
SAIVMS=Scottish Audit of Intracranial Vascular Malformations. 
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patients with a CCM have other strong indications for 
their use to prevent occlusive vascular disease. The 
possibility that antithrombotic therapy reduces the risk 
of intracranial haemorrhage and focal neurological 
deficit from a CCM, perhaps by preventing thrombus 
formation that might trigger these events, raises a 
hypothesis that should be tested in a planned randomised 
controlled trial in people with CCM with or without other 
indications for antithrombotic therapy.
In summary, we did not find any evidence of a harmful 
association between the use of antithrombotic therapy 
and intracranial haemorrhage from a CCM in the popu-
lation-based study and hospital-based studies, which 
included a range of patients with sporadic and fam-
ilial CCM. The possibility that antithrombotic therapy 
might be beneficial for the prevention of intracranial 
haemorrhage from CCMs should be investigated in a 
randomised controlled trial.
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